Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria
Public ClinicalTrials.gov record NCT03520036. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria
Study identification
- NCT ID
- NCT03520036
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Tanabe Pharma America, Inc.
- Industry
- Enrollment
- 102 participants
Conditions and interventions
Conditions
Interventions
- MT-7117 low dose Drug
- MT-7117 high dose Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 4, 2018
- Primary completion
- Sep 27, 2019
- Completion
- Sep 27, 2019
- Last update posted
- Dec 30, 2025
2018 – 2019
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ACTCA, A Member of the Alliance, Inc. | Los Angeles | California | 90036 | — |
| University of California at San Francisco | San Francisco | California | 94143 | — |
| University of Miami Miller School of Medicine | Miami | Florida | 33136 | — |
| Metro Boston Clinical Partners, LLC | Brighton | Massachusetts | 02135 | — |
| Ichan School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Wake Forest Baptist Medical Center | Winston-Salem | North Carolina | 27157 | — |
| Remington-Davis, Inc | Columbus | Ohio | 43215 | — |
| University of Texas Medical Branch Porphyria Center | Galveston | Texas | 77555 | — |
| University of Utah | Salt Lake City | Utah | 84108 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03520036, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 30, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03520036 live on ClinicalTrials.gov.